Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Tobacco Dependence in People With Mental Health and Addictive Disorders

  • Substance Use and Related Disorders (JR McKay, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

People with mental health and addictive disorders (MHADs) have higher rates of cigarette smoking, and less success in quitting smoking compared with the general population. Moreover, tobacco-related medical illness may be the leading cause of death in the MHAD population. We discuss the scope of this comorbidity, and approaches to the treatment of tobacco dependence in people with MHAD, including schizophrenia, mood disorders, anxiety disorders, and alcohol and substance use disorders. Finally, at the level of health systems, we emphasize the importance of integrated treatment of tobacco dependence in MHADs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Giovino GA. The tobacco epidemic in the United States. Am J Prev Med. 2007;33:318–26.

    Article  Google Scholar 

  2. Center for Disease Control. CDC. Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000–2004. MMWR. 2008;57:1226–8.

    Google Scholar 

  3. Schroeder SA, Warner KE. Don’t forget tobacco. N Engl J Med. 2010;363:201–4.

    Article  PubMed  CAS  Google Scholar 

  4. •• Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. J Am Med Assoc. 2000;284:2606–10. An important population-based study of smoking prevalence in persons with and without current and past histories of mental illness based on data from the National Comorbidity Study (NCS), suggesting that persons with mental illness consume a disproportionate amount of cigarettes compared to the general population.

    Article  CAS  Google Scholar 

  5. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61:1107–15.

    Article  PubMed  Google Scholar 

  6. Hitsman B, Moss TG, Montoya ID, George TP. Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry. 2009;54:368–78.

    PubMed  Google Scholar 

  7. Tidey JW, Rosenhow DJ, Kaplan GB, Swift RM. Subjective and physiological responses to smoking cues in smokers with schizophrenia. Nicotine Tob Res. 2005;7:421–9.

    Article  PubMed  Google Scholar 

  8. Brown S, Inskip H, Barraclough B. Causes of excess mortality in schizophrenia. Br J Psychiatry. 2000;177:212–7.

    Article  PubMed  CAS  Google Scholar 

  9. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risk of cardiovascular disease. Am Heart J. 2005;150:1115–21.

    Article  PubMed  Google Scholar 

  10. Hser YI, McCarthy WJ, Anglin MD. Tobacco use as a distal predictor of mortality among long-term narcotic addicts. Prev Med. 1994;23:61–9.

    Article  PubMed  CAS  Google Scholar 

  11. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. role of tobacco use in a community-based cohort. JAMA. 1996;275:1097–103.

    Article  PubMed  CAS  Google Scholar 

  12. Morisano D, Bacher I, Audrain-McGovern J, George TP. Mechanisms underlying the co-morbidity of tobacco use in mental health and addictive disorders. Can J Psychiatry. 2009;54:356–67.

    PubMed  Google Scholar 

  13. •• Wing VC, Wass CE, Soh DW, George TP. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann NY Acad Sci. 2012;1248:89–106. A recent review of neurobiological risk factors that predispose to the initiation and maintenance of tobacco dependence in people with schizophrenia.

    Article  PubMed  CAS  Google Scholar 

  14. Lo S, Heishman SJ, Raley H, et al. Tobacco craving in smokers with and without schizophrenia. Schizophr Res. 2011;127:241–5.

    Article  PubMed  Google Scholar 

  15. Montoya ID, Herbeck DM, Svikis DS, et al. Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice. Am J Addict. 2005;14:441–54.

    Article  PubMed  Google Scholar 

  16. Berk M, Ng F, Wang WV, et al. 2008: going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord. 2008;110:126–34.

    Article  PubMed  Google Scholar 

  17. Desai HD, Seabolt J, Jann MW. Smoking inpatients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15:469–94.

    Article  PubMed  CAS  Google Scholar 

  18. Weinberger AH, Reutenauer EL, Allen TM, et al. Reliability of the Fagerstrom test for nicotine dependence, Minnesota nicotine withdrawal scale, and Tiffany questionnaire for smoking urges in smokers with and without schizophrenia. Drug Alcohol Depend. 2007;86:278–82.

    Article  PubMed  CAS  Google Scholar 

  19. •• Kelly DL, Raley HG, Lo S, et al. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophr Bull. 2012;38:543–51. A cross-sectional study, which suggested that smokers with schizophrenia compared with non-psychiatric smokers report greater reward perception and social facilitation, poor social pressure to quit smoking and less perception of tobacco-related health risks of smoking.

    Article  PubMed  Google Scholar 

  20. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23:247–54.

    Article  PubMed  CAS  Google Scholar 

  21. Addington J, El-Guebaly N, Campbell W, et al. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry. 1998;155:974–6.

    PubMed  CAS  Google Scholar 

  22. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835–42.

    Article  PubMed  CAS  Google Scholar 

  23. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163:1934–42.

    Article  PubMed  Google Scholar 

  24. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27:380–6.

    Article  PubMed  CAS  Google Scholar 

  25. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63:1092–6.

    Article  PubMed  CAS  Google Scholar 

  26. Chou KR, Chen R, Lee JF, et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud. 2004;41:321–30.

    Article  PubMed  Google Scholar 

  27. Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3:397–403.

    Article  PubMed  CAS  Google Scholar 

  28. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218–25.

    Article  PubMed  CAS  Google Scholar 

  29. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–201.

    Article  PubMed  CAS  Google Scholar 

  30. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53–61.

    Article  PubMed  CAS  Google Scholar 

  31. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008;16:CD006103.

    Google Scholar 

  32. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164:1269.

    Article  PubMed  Google Scholar 

  33. Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry. 2008;165:774.

    Article  PubMed  Google Scholar 

  34. • Williams JM, Anthenelli RM, Morris C, et al. A double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline tartrate for smoking cessation in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2012;73:654–60. The first multi-center double-blind, placebo-controlled evaluation of the safety and efficacy of varenicline for smoking cessation in smokers with schizophrenia and schizoaffective disorder.

    Article  PubMed  CAS  Google Scholar 

  35. Isensee B, Wittchen H, Stein MB, et al. Smoking increases the risk of panic: findings from a prospective community sample. Arch Gen Psychiatry. 2003;60:692–700.

    Article  PubMed  Google Scholar 

  36. Zvolensky MJ, Forsyth JP, Fuse T, et al. Smoking and non-clinical panic attacks: an initial empirical test of panic-relevant cognitive processes. Cog Behavior Therapy. 2002;31:170–82.

    Article  Google Scholar 

  37. Ziedonis DM, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: national institute of mental health report. Nicotine Tob Res. 2008;10:1691–715.

    Article  PubMed  Google Scholar 

  38. Beckham JC, Roodman AA, Shipley RH, et al. Smoking in Vietnam combat veterans with post-traumatic stress disorder. J Trauma Stress. 1995;8:461–72.

    Article  PubMed  CAS  Google Scholar 

  39. Beckham JC, Kirby AC, Feldman ME, et al. Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder. Addict Behav. 1997;22:637–47.

    Article  PubMed  CAS  Google Scholar 

  40. Op Den Velde W, Aarts PG, Falger PR, et al. Alcohol use, cigarette consumption, and chronic post-traumatic stress disorder. Alcohol Alcohol. 2002;37:355–61.

    Google Scholar 

  41. McFall M, Saxon AJ, Thompson CE, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. Am J Psychiatry. 2005;162:1311–9.

    Article  PubMed  Google Scholar 

  42. Hertzberg MA, Moore SD, Feldman ME, et al. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic post-traumatic stress disorder. J Clin Psychopharmacol. 2001;21:94–8.

    Article  PubMed  CAS  Google Scholar 

  43. •• McFall M, Saxon AJ, Malte CA, et al. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized clinical trial. JAMA. 2010;304:2485–93. A pivotal multi-center VA Cooperative Study comparing integrated versus separate mental health and tobacco treatment in smokers with post-traumatic stress disorder.

    Article  PubMed  CAS  Google Scholar 

  44. Prochaska JJ. Integrating tobacco treatment into mental health settings. JAMA. 2010;304:2534–5.

    Article  PubMed  CAS  Google Scholar 

  45. Acton GS, Prochaska JJ, Kaplan AA, et al. Depression and stages of change for smoking in psychiatric outpatients. Addict Behav. 2001;26:621–31.

    Article  PubMed  CAS  Google Scholar 

  46. Haug NA, Hall SM, Prochaska JJ, et al. Acceptance of nicotine dependence treatment among currently depressed smokers. Nicotine Tob Res. 2005;7:217–24.

    Article  PubMed  Google Scholar 

  47. Breslau N, Johnson EO. Predicting smoking cessation and major depression in nicotine-dependent smokers. Am J Public Health. 2000;90:1122–227.

    Article  PubMed  CAS  Google Scholar 

  48. Breslau N, Peterson EL, Schultz LR, et al. Major depression and stages of smoking. a longitudinal investigation. Arch Gen Psychiatry. 1998;55:161–6.

    Article  PubMed  CAS  Google Scholar 

  49. Weinberger AH, George TP, McKee SA. Differences in smoking expectancies in smokers with and without a history of major depression. Addict Behav. 2010;36:434–7.

    Article  PubMed  Google Scholar 

  50. Thorsteinsson HS, Gillin JC, Patten CA, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology. 2001;24:350–8.

    Article  PubMed  CAS  Google Scholar 

  51. Evins AE, Culhane MA, Alpert JE, et al. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmcol. 2008;28:660–6.

    Article  CAS  Google Scholar 

  52. Hall SM, Tsoh JY, Prochaska JJ, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health. 2006;10:1808–14.

    Article  Google Scholar 

  53. • MacPherson L, Tull MT, Matusiewicz AK, et al. Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. J Consult Clin Psychol. 2010;78:55–61. A well-designed randomized trial of a novel behavioral intervention for smoking cessation in depressed smokers.

    Article  PubMed  Google Scholar 

  54. Vickers KS, Patten CA, Lewis BA, et al. Feasibility of an exercise counseling intervention for depressed women smokers. Nicotine Tob Res. 2009;8:985–95.

    Article  Google Scholar 

  55. Philip NS, Carpenter LL, Tyrka AR, et al. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009;70:1026–31.

    Article  PubMed  CAS  Google Scholar 

  56. Chengappa KNR, Kambhampati RK, Perkins K, et al. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J Clin Psychiatry. 2001;62:503–8.

    Article  PubMed  CAS  Google Scholar 

  57. Trockel M, Burg M, Jaffe A, et al. Smoking behavior postmyocardial infarction among ENRICHD trial participants: cognitive behavior therapy intervention for depression and low perceived social support compared with care as usual. Psychosom Med. 2008;70:875–82.

    Article  PubMed  Google Scholar 

  58. Weinberger AH, Vessicchio JC, Sacco KC, et al. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. J Clin Psychopharmacol. 2008;28:584–7.

    Article  PubMed  Google Scholar 

  59. Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. J Dual Diagnosis. 2012;2:131–2.

    Google Scholar 

  60. Weinberger AH, Sofuoglu M. The impact of cigarette smoking on stimulant addiction. Am J Drug Alcohol Abuse. 2009;35:12–7.

    Article  PubMed  Google Scholar 

  61. Hays JT, Schroeder DR, Offord KP, et al. Response to nicotine dependence treatment in smokers with current and past alcohol problems. Ann Behav Med. 1999;21:244–50.

    Article  PubMed  CAS  Google Scholar 

  62. • Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. J Subst Abuse Treat. 2006;30:213–7. A large study of high- versus low dose transdermal nicotine for smoking cessation in smokers in early alcohol recovery.

    Article  PubMed  Google Scholar 

  63. • Kalman D, Herz L, Monti P, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. Drug Alcohol Depend. 2011;118:111–8. A large study comparing the addition of bupropion SR to transdermal nicotine for smoking cessation in smokers in early alcohol recovery.

    Article  PubMed  CAS  Google Scholar 

  64. Hays JT, Hurt RD, Decker PA, et al. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine Tob Res. 2009;11:859–67.

    Article  PubMed  CAS  Google Scholar 

  65. •• Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72:1144–56. An outstanding meta-analysis of smoking cessation interventions in smokers with comorbid substance misuse that suggested the safety of concurrent versus sequential interventions for treating comorbid tobacco and other substance abuse.

    Article  PubMed  Google Scholar 

  66. Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol. 2004;65:681–91.

    PubMed  Google Scholar 

  67. Nieva G, Ortega LL, Mondona S. Simultaneous versus delayed treatment of tobacco dependence in alcohol-dependent outpatients. Eur Addict Res. 2010;17:1–9.

    Article  PubMed  Google Scholar 

  68. Hays JT, Croghan IT, Schroeder DR, et al. Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study. J Subst Abuse Treat. 2011;41:102–7.

    Article  Google Scholar 

  69. McKee SA, Harrison ELR, O’Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66:185–90.

    Article  PubMed  CAS  Google Scholar 

  70. Nahvi S, Richter K, Li X, et al. Cigarette smoking and interest in quitting in methadone maintenance patients. Addict Behav. 2006;31:2127–34.

    Article  PubMed  Google Scholar 

  71. Poling J, Rounsaville B, Gonsai K, et al. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict. 2010;19:401–8.

    Article  PubMed  Google Scholar 

  72. Okoli CTC, Khara M, Procyshyn RM, et al. Smoking cessation interventions among individuals in methadone maintenance: a brief review. J Subst Abuse Treat. 2010;38:191–9.

    Article  PubMed  Google Scholar 

  73. Moss TG, Weinberger AH, Vessicchio JC, et al. A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities. Am J Addict. 2010;19:293–311.

    PubMed  Google Scholar 

  74. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of 10-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45–53.

    Article  PubMed  Google Scholar 

  75. George TP, Ziedonis DM. Addressing tobacco dependence in psychiatric practice: promises and pitfalls. Can J Psychiatry. 2009;54:353–5.

    PubMed  Google Scholar 

  76. George TP. Nicotine and tobacco. In: Goldman L, Schaffer A, editors. Cecil textbook of medicine. 24th ed. New York, NY: Elsevier; 2011. p. 2672.

Download references

Acknowledgments

This work was supported in part by the Chair in Addiction Psychiatry at the University of Toronto (to T. P. George), and grant support from the National Institute on Drug Abuse (NIDA; 2U01-DA-020830-07, to Caryn Lerman, Rachel Tyndale, and T. P. George; R03-DA027052, to A. H. Weinberger), the Canadian Institutes of Health Research (CIHR; MOP#115145, to T. P. George), and the Ontario Mental Health Foundation (to T. P. George).

Disclosure

K. M. Mackowick: none; M.-J. Lynch: none; A. H. Weinberger: funding from NIDA (R03-DA027052); T. P. George: member of Novartis Data Monitoring Committee; consultant to Janssen-Ortho and Pfizer; payment for serving on speakers bureaus for Pfizer, AstraZeneca, and Janssen-Ortho; grants from National Institute on Drug Abuse, Canadian Institutes of Health Research, Ontario Mental Health Foundation, and Pfizer; royalties from Taylor & Francis.

Author information

Authors and Affiliations

  1. Intramural Research Program, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, MD, USA

    Kristen M. Mackowick

  2. Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada

    Kristen M. Mackowick

  3. Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto, Toronto, ON, Canada

    Marie-Josee Lynch & Tony P. George

  4. Schizophrenia Program, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada, M5T 1R8

    Marie-Josee Lynch & Tony P. George

  5. Division of Substance Abuse, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

    Andrea H. Weinberger & Tony P. George

  6. Cancer Prevention and Control Research Program, Yale Cancer Center, New Haven, CT, USA

    Andrea H. Weinberger

Authors
  1. Kristen M. Mackowick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Josee Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea H. Weinberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tony P. George
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tony P. George.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mackowick, K.M., Lynch, MJ., Weinberger, A.H. et al. Treatment of Tobacco Dependence in People With Mental Health and Addictive Disorders. Curr Psychiatry Rep 14, 478–485 (2012). https://doi.org/10.1007/s11920-012-0299-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-012-0299-2

Keywords

Search

Navigation